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Background: We carried out a candidate gene association study in pediatric acute lymphoblastic leukemia (ALL) to
identify possible genetic risk factors in a Hungarian population.
Methods: The results were evaluated with traditional statistical methods and with our newly developed Bayesian
network based Bayesian multilevel analysis of relevance (BN-BMLA) method. We collected genomic DNA and
clinical data from 543 children, who underwent chemotherapy due to ALL, and 529 healthy controls. Altogether 66
single nucleotide polymorphisms (SNPs) in 19 candidate genes were genotyped.
Results: With logistic regression, we identified 6 SNPs in the ARID5B and IKZF1 genes associated with increased risk
to B-cell ALL, and two SNPs in the STAT3 gene, which decreased the risk to hyperdiploid ALL. Because the
associated SNPs were in linkage in each gene, these associations corresponded to one signal per gene. The odds
ratio (OR) associated with the tag SNPs were: OR = 1.69, P = 2.22x10-7 for rs4132601 (IKZF1), OR = 1.53, P = 1.95x10-5
for rs10821936 (ARID5B) and OR= 0.64, P = 2.32x10-4 for rs12949918 (STAT3). With the BN-BMLA we confirmed the
findings of the frequentist-based method and received additional information about the nature of the relations
between the SNPs and the disease. E.g. the rs10821936 in ARID5B and rs17405722 in STAT3 showed a weak
interaction, and in case of T-cell lineage sample group, the gender showed a weak interaction with three SNPs in
three genes. In the hyperdiploid patient group the BN-BMLA detected a strong interaction among SNPs in the
NOTCH1, STAT1, STAT3 and BCL2 genes. Evaluating the survival rate of the patients with ALL, the BN-BMLA showed
that besides risk groups and subtypes, genetic variations in the BAX and CEBPA genes might also influence the
probability of survival of the patients.
Conclusions: In the present study we confirmed the roles of genetic variations in ARID5B and IKZF1 in the
susceptibility to B-cell ALL. With the newly developed BN-BMLA method several gene-gene, gene-phenotype and
phenotype-phenotype connections were revealed. We showed several advantageous features of the new method,
and suggested that in gene association studies the BN-BMLA might be a useful supplementary to the traditional
frequentist-based statistical method.
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Pediatric acute lymphoblastic leukemia (ALL) is a
clonal disease of a lymphoblast and the most common
malignancy of all childhood cancers. It is generally
accepted that tumorogenesis results from complex inter-
play between inherited genetic background and specific
environmental exposure [1]. In the last decade several
genome wide and candidate gene association studies
have been carried out and revealed a number of genes
and genetic variations, which might influence the risk to
the disease [2-6]. In gene association studies, due to the
high number of inconclusive results, it is generally
accepted that the role of a gene or a genetic variation
can only be acknowledged, if it is confirmed by inde-
pendent studies.
In gene association studies it is well-known, that
the traditional frequentist-based statistical methods
have several limitations, like the difficult handling of the
multiple testing problem and model complexity, the
inappropriate approach towards complex traits (i.e. dis-
regarding the role of high-number of weak factors, gene-
gene interactions, pathway-based interpretation), and
the high redundancy of predictors, e.g. the discovery of
non-causal, transitively associated descriptors [7,8].
Recently, we have introduced a new statistical method-
ology, named Bayesian network based Bayesian multi-
level analysis of relevance (BN-BMLA), which supports
association analysis by estimating posteriors of strong
relevance [9-11]. First, we tested the BN-BMLA method
in a case–control setup using artificial datasets for iden-
tifying interactions and conditional relevance [12]. The
BN-BMLA was proven to be superior over other multi-
variate methods using conditional models designed to
detect associations between genotypic variables and the
target variable. Later, we also tested the method in a real
world dataset of a partial genome association study in
asthma [13]. In this latter study we found that next to
the directly associated genes identified by the
frequentist-based methods (χ2 test, multivariate logistic
regression and multifactor dimensionality reduction),
the BN-BMLA could detect plausible additional genes
involved in gene-gene interactions or genes which were
indirectly associated with asthma, i.e. showed transitive
association via other variables (e.g. via rhinitis).
As could be seen from the results, the advantage was
not only that the BN-BMLA could detect more relevant
variables, but the Bayesian networks offered a rich lan-
guage for the detailed representation of types of rele-
vance, including causal, acausal, and multitarget aspects.
Additionally, Bayesian statistics offers an automated and
normative solution for the multiple hypothesis testing
problems. The BN-BMLA extends the scope of local
‘causal’ discovery methods, and because of the direct in-
terpretation of Bayesian posteriors, contrary to p-valuesfrom the frequentist-based approach, makes it an ideal
candidate for creating probabilistic knowledge bases
to support off-line meta-analysis and fusion of back-
ground knowledge.
In the present study we use a traditional frequentist-
based method (logistic regression) and the BN-BMLA
for evaluating the results of a candidate gene association
study in ALL. From the scientific literature and data-
bases we selected 66 SNPs in 19 known candidate genes
and investigated with the two methods whether the
presence of these polymorphisms was associated with
ALL in our population, and whether any of these alleles
influenced some disease characteristics and the outcome
of the therapy in the affected individuals.
Methods
Study population and definitions
In a retrospective manner, DNA was obtained from 543
children (mean age at diagnosis: 6.4 ± 4.2 years) who
underwent chemotherapy due to acute lymphoblastic
leukemia. Patients were diagnosed with ALL between
1990 and 2010, aged 1–15 years at diagnosis and treated
according to the ALL Berlin-Frankfurt-Münster (BFM)
90, 95 and 2002 chemotherapy protocols in ten Hungar-
ian centres.
We stratified our patients in different risk groups
according to the following criteria: Low risk (LR) group
included children aged 1–6 years who have a white
blood cell count of less than 20,000/μl at diagnosis,
good prednisone response and no-T-ALL. High risk
(HR) group included poor prednisone response, and/or
evidence of t(9;22) (or BCR/ABL), and/or evidence of
t(4;11) (or MLL/AF4). Medium risk (MR) group included
children with no HR or LR criteria. Prednisone responses
were determined after 8 and 33 days of induction
treatment. The presence of 1,000 blast/μl or more in
the peripheral blood on day 8 and/or >5% blast in
the bone marrow on day 33 were defined as poor pred-
nisone response.
There is no significant difference in the distribution of
age groups or genders or ALL-immunophenotypes be-
tween the whole population and our sample-collection.
The 529 control patients (aged 16.1 ± 12.4 years) of the
same ethnicity and from the same geographical region as
the patients were randomly selected from healthy blood
donors and from minor outpatients from the Ortho-
paedic Department in the Budai Children’s Hospital, and
from the Urological Department of Heim Pal Pediatric
Hospital, Budapest. None of the controls have had child-
hood ALL or any other types of cancers previously. In
Table 1, some clinical characteristics of ALL patients
and controls are presented.
All study subjects belonged to the Hungarian (Cauca-
sian) population. Informed consent was requested from
Table 1 Some characteristics of ALL patients and controls
in the study population
Characteristics Subgroups ALL Controls
Total number of subjects 543 529
Gender n (%) Male 308 (56.7) 305 (57.7)
Female 235 (43.3) 224 (42.3)
Age at diagnosis,
years (mean±SD)
6.4±4.2 16.1±12.4
Number of subjects n (%) <1 year 8 (1.5) -
1-10 years 422 (77.7) 200 (37.8)
>10 years 107 (19.7) 329 (62.2)
N/D 6 (1.1) -
Risk group n (%) LR 96 (17.7) -
MR 309 (56.9) -
HR 55 (10.1) -
Protocols n (%) 90 131 (24.1) -
95 250 (46.0)
2002 120 (22.1) -
N/D 42 (7.7)
Immunphenotype n (%) B-ALL 390(71.8) -
T-ALL 78 (14.4) -
Cytogenetics n (%) Hyperdiploidy 79 (14.5) -
Overall survival n (%) 516* 414 (85.5)* -
Event free survival n (%) 516* 418 (81.0)* -
N/D: no data available; LR: Low risk, MR: Medium risk; HR: High risk, *see
details in the text.
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study was conducted according to the principles
expressed in the Declaration of Helsinki and was
approved by the Hungarian Scientific and Research Eth-
ics Committee of the Medical Research Council (ETT
TUKEB; Case No.:8-374/2009-1018EKU 914/PI/08.)Candidate gene selection
From the scientific literature we selected 19 candidate
genes, which in earlier studies were seemed to be rele-
vant to ALL. We selected genes from the results of
GWA studies, candidate gene association studies and
from other studies in which the investigated pathways
could also be important for ALL. In online databases we
searched SNPs for these 19 genes. Altogether 66 SNPs
were selected. The selection criterion was: minor allele
frequency > 10%. The SNPs were prioritized according to
their published role in ALL, and their estimated func-
tionality. In some cases (e.g. in ARIDB5, IKZF1 genes)
SNPs were selected, which showed strong linkage dis-
equilibrium with other investigated SNPs in the HapMap
database [14]. This could serve as genotyping controls,
but during the BN-BMLA evaluation tag SNPs werechosen for the analysis. Table 2 shows information about
the selected genes and SNPs.
Laboratory methods, genotyping
Genomic DNA from children with leukemia was
obtained retrospectively from whole, peripheral blood
taken in remission phase using by QIAmp DNA Blood
Maxi Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Before DNA extraction the
normal leukocyte cell count was checked by FACS. We
used only those samples where the normal cell count
was over 5 G/l. DNA from healthy control samples was
isolated from whole peripheral blood using iPrep Pure-
Link gDNA Blood Kit, iPrep Purification Instrument
(Invitrogen, Life Technologies Co., Grand Island, USA).
Genotyping was carried out by Sequenom iPLEX Gold
MassARRAY technology at the McGill University and
Génome Québec Innovation Centre, Montréal, Canada.
Only those SNPs were included in the analysis, which
have a genotyping call rate over 90%.
Frequentist-based statistical analysis
Allele frequencies were calculated by allele counting.
Hardy-Weinberg equilibrium was tested by using a χ2
goodness-of-fit test with an acceptable cut off value of
p ≥ 0.01 (online application: [15]).
The distributions of alleles and genotypes in cases and
controls were compared by means of the χ2 test [15].
Association between the candidate SNPs and the suscep-
tibility to childhood acute lymphoblastic leukemia was
tested using gender adjusted logistic regression in the
case–control data performed by IBM SPSS Statistics
software (version 19.0). Confidence interval was calcu-
lated at the 95% level (C.I. 95%). Multiple testing correc-
tions were performed using the Benjamini-Hochberg false
discovery rate (FDR) method with type I error rate of 1%.
Haplotype analyses were carried out by Haploview ver-
sion 4.2 software (Broad Institute, Cambridge, Maine,
USA). Odds ratios for haplotypes were calculated by
MedCalc 12.1.1 software (MedCalc Software, Maria-
kerke, Belgium). Survival analyses were performed using
Kaplan-Meier method. The log-rank test was applied for
evaluating the association between survival and cate-
gorized parameters, as risk group, gender, and study-
protocols. The statistical tests were carried out by IBM
SPSS Statistics software, version 19.0.
Bayesian Network based Bayesian Multilevel Analysis
A Bayesian Network (BN) is a probabilistic graphical
model that represents the conditional dependencies of a
set of random variables with a directed acyclic graph
(DAG). A BN can efficiently describe the joint probabil-
ity distribution of the variables. A node of the graph
Table 2 Some information about the selected genes and SNPs
SNP (rs#) Gene Alleles (1/2)a Positionb Functionc
rs2066853 AhR G/A chr7:17345635 missense/Arg>Lys
rs713150* AhR C/G chr7:17306682 intron
rs2282885 AhR T/C chr7:17312139 intron
rs2282883 AhR G/A chr7:17322872 intron
rs2237297 AhR C/T chr7:17326119 intron
rs10994982* ARID5B A/G chr10:63380110 intron
rs10821936 ARID5B T/C chr10:63393583 intron
rs7089424 ARID5B T/G chr10:63422165 intron
rs4948502 ARID5B T/C chr10:63509423 intron
rs4948496 ARID5B T/C chr10:63475623 intron
rs4948487 ARID5B A/C chr10:63339871 intron
rs4506592 ARID5B G/A chr10:63397193 intron
rs4509706 ARID5B T/C chr10:63331346 near-gene-5
rs3817074 BAX C/T chr19:54151024 intron
rs7259013 BAX A/C chr19:54155096 intron
rs11667351 BAX T/G chr19:54147966 near-gene-5
rs12457893 BCL2A A/C chr18:59077141 intron
rs11876772 BCL2A A/G chr18:58968686 intron
rs2850761 BCL2A A/G chr18:59117377 intron
rs8092560 BCL2A T/A chr18:58954673 intron
rs4987845 BCL2A G/A chr18:58946168 untranslated-3
rs1801018 BCL2B A/G chr18:59136859 coding-synon/Thr>Thr
rs1893806 BCL2B T/G chr18:59135944 near-gene-3
rs1799988 CCR5 C/T chr3:46387263 untranslated-5
rs3087253 CCR5 T/C chr3:46393693 near-gene-3
rs11575815 CCR5 T/A chr3:46395174 unknown
rs10403561 CEBPA A/G chr19:38482342 near-gene-3
rs874966 CEBPA A/G chr19:38481237 near-gene-3
rs2239633 CEBPE C/T chr14:22658897 near-gene-5
rs8015478 CEBPE C/A chr14:22655858 near-gene-3
rs12434881 CEBPE G/A chr14:22658482 near-gene-5
rs11978267 IKZF1 A/G chr7:50433798 intron
rs4132601 IKZF1 T/G chr7:50438098 untranslated-3
rs6954833 IKZF1 A/G chr7:50425940 intron
rs10235796 IKZF1 C/T chr7:50430131 intron
rs6964969 IKZF1 A/G chr7:50440745 near-gene-3
rs11208538** JAK1 G/C chr1:65161877 intron
rs310225 JAK1 G/A chr1:65097271 intron
rs12063205 JAK1 A/G chr1:65144640 intron
rs3212713 JAK3 G/A chr19:17816001 intron
rs11888 JAK3 T/C chr19:17796626 near-gene-3
rs2229974 NOTCH1 T/C chr9:138511457 coding-synon/Asp>Asp
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Table 2 Some information about the selected genes and SNPs (Continued)
rs3124596 NOTCH1 A/G chr9:138521325 intron
rs3124999 NOTCH1 C/T chr9:138515294 intron
rs3124603 NOTCH1 T/C chr9:138529998 intron
rs1800566 NQO1 C/T chr16:68302646 missense/Pro>Ser
rs1469908 NQO1 A/G chr16:68321913 unknown
rs1143684 NQO2 T/C chr6:2955389 missense/Leu>Phe
rs2756075 NQO2 C/T chr6:2949532 intron
rs4149352 NQO2 C/T chr6:2947237 intron
rs2070999 NQO2 G/A chr6:2944728 near-gene-5
rs4149360* NQO2 G/A chr6:2951806 intron
rs2030171 STAT1 G/A chr2:191577408 intron
rs10208033 STAT1 T/C chr2:191587662 near-gene-5
rs3088307 STAT1 G/C chr2:191537657 untranslated-3
rs12949918 STAT3 T/C chr17:37779799 intron
rs3809758 STAT3 G/A chr17:37725506 intron
rs3816769 STAT3 T/C chr17:37751799 intron
rs17405722 STAT3 G/A chr17:37796027 near-gene-5
rs7217728 STAT5A T/C chr17:37700927 intron
rs3198502 STAT5A G/T chr17:37716520 untranslated-3
rs9906933 STAT5B G/A chr17:37663571 intron
rs4029774 STAT5B A/G chr17:37682487 near-gene-5
rs703817 STAT6 G/A chr12:55776095 untranslated-3
rs3024979 STAT6 T/A chr12:55774560 intron
rs324015 STAT6 G/A chr12:55776367 untranslated-3
*Failed genotyping, **Monomorphic, aAlleles on the forward strand; 1- major allele; 2-risk allele, bPosition according to NCBI Genome Build 36.0, cFunction
according to CHIP Bioinformatics Tools http://snpper.chip.org/.
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dependency between the corresponding variables.
Structure learning is finding a DAG that best describes
the dataset. However, in most cases, where the amount
of available data is modest relative to the number
of variables, usually there are many DAGs that have
non-negligible a posteriori probabilities. Even in these
cases, there might be certain structural features, e.g. the
presence of an edge, which we can extract reliably. The
Bayesian learning framework enables us to estimate a
posteriori probability of a certain feature f as follows
P f jDð Þ ¼
X
G
f Gð ÞP G Dj Þð ð1Þ
where G represents a BN structure, D is the dataset, and
f(G) is an indicator function of the presence of f in G, i.e.
it is 1 if the feature holds in G and 0 otherwise.
We use Bayes’ theorem to calculate P(G|D), and we
have that P G Dj Þ / P D Gj ÞP Gð Þðð . Assuming that there
are no missing values in the dataset D, the variables
are multinomial with a Dirichlet parameter prior forevery possible instantiations of their parents, and the
prior P(G) satisfies some general constraints, then the
term P(D|G) (i.e. the marginal likelihood of the data)
can be computed efficiently in a closed form [16]. The
other term, P(G) is the a priori probability of a struc-
ture G. We use uniform prior over structures in our
experiments and the K2 hyperparameter prior, as pro-
posed by Cooper and Herskovits [16].
Because the number of BN structures is super-
exponential in the number of nodes, exact summation of
all possible structures G is computationally intractable.
We use Metropolis-coupled Markov Chain Monte Carlo
(MC3) methods [17] over the space of DAGs for the ap-
proximation of Eq.1. We run the Metropolis-coupled
Markov Chain sampler with a burn-in period of 2x107
steps and then collect 6x107 samples (i.e. network struc-
tures). We restrict the space of the possible structures
limiting the number of parents per node to 4. To ensure
the convergence of the posterior of the structural
features estimated by the MCMC, we use Gelman-Rubin
R-scores [18] and Geweke Z-scores [19]. All reported
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scores also confirmed convergence.
We computed a posteriori probabilities for structural
features summarized in Table 3, and as an illustration
see Figure 1.
The current implementation of our method deals
with only discrete variables. Continuous covariates have
to be discretized first in order to include them in the
BN-BMLA analysis. In this paper, we use only discrete
variables (SNPs, gender, case/control status, 5-year
survival).
Computing redundancies and interactions
In a post-processing step, we can compute the a poster-
iori probability of the strong relevance of any set of vari-
ables with a given size k [9,10]. The a posteriori
probability of the sub-relevance of a k-sized set s is
denoted with a special notation as follows

p sjDð Þ ¼
P MBS Yð Þ ¼ sjDð Þ þ
X
s⊂s0
P MBS Yð Þ ¼ s0 Dj Þð , where the
terms are the MBS posterior of the set s and the MBS
posteriors for all its superset.
We calculate the interaction or redundancy [10] of a vari-
able set Xi1 ; . . . ;Xinf g by computing R ¼ 
p Xi1 ;...;Xinf gjDð ÞYn
k¼1
p Xikf gjDð Þ
.
Where the numerator is the a posteriori probability
that the variable set is strongly relevant with respect to
the target variable, and the denominator is the product
of the a posteriori probability of the strong relevance of
the variables in the set.
If R equals 1, this means that the approximation of the
strong relevance of the set under an independence
assumption (i.e. the denominator) is equal to the real a
posteriori probability of the set (i.e. the numerator). InTable 3 Structural features that indicate different dependenc
Relation Abbreviation
Pairwise features
Direct causal relevance DCR(X,Y)
Transitive causal relevance TCR(X,Y)
Confounded relevance ConfR(X,Y)
Association A(X,Y)
Pure interactionist relevance PIR(X,Y)
Strong relevance SR(X,Y)
Relevance of variable sets
Strong relevance MBS(Y)
Interaction models of relevant variables
Strong relevance MBG(Y)this case, the variables in the set are independently rele-
vant (i.e. they are independently present or absent in the
Markov Blanket set of the target variable).
If R differs from 1, it indicates an interaction (R> 1) or
a redundancy (R< 1). The corresponding Interaction Ratio
is then =ln(R), and the Redundancy Ratio is RR=–ln(R).
Results
SNPs associated with ALL risk
As the blood sample was taken retrospectively and in
remission, and only those samples were used where the
normal leukocyte cell count was over 5 G/l, practically
no tumour cells were in our samples, thus we investi-
gated only normal cells and germline polymorphisms.
From the 66 genotyped SNPs one SNP was mono-
morphic (minor allele frequency = 0), and three had
poor genotyping results (poor genotype clusters or low
call rates), leaving 62 SNPs for frequentist and BN-
BMLA analyses.
Minor allele and genotype frequencies in controls and
ALL patients are presented in Additional file 1. The
results of the statistical analysis of all genotyping data
are presented in Additional file 2.
The differences in allele and genotype frequencies be-
tween ALL cases and controls were nominally significant
(P < 0.05) for 20 SNPs. But, when gender adjusted logis-
tic regression analysis with false discovery rate of (FDR
(α)=) 1% significance threshold was calculated, the dif-
ferences remained significant (P < 3.42E-04) only in cases
of 6 SNPs in two genes (rs10821936, rs7089424 and
rs4506592 in ARID5B, and rs6964969, rs11978267 and
rs4132601 in IKZF1, as shown in Table 4). These results
indicate that these SNPs are associated with increased
susceptibility to ALL with odds ratios between 1.4 and
1.5. Then we analyzed whether the number of risk allelese types between the variables
Graphical
There is an edge between X and Y
There is directed path between X and Y
X and Y have common ancestor
DCR or TCR or ConfR
X and Y have common child
PIR or DCR
The set consisting of Y’s parents, its children, and the other parents
of its children (the Markov Blanket Set of Y)
The subgraph that includes the nodes in the MBS and the incoming
edges into Y and into its children (the Markov Blanket Subgraph of Y)
ALL
rs4509706
ARID5B
rs4948487
ARID5B
rs4948496
ARID5B
rs4948502
ARID5B
rs10235796
IKZF1
rs6954833
IKZF1
rs10821936
ARID5B
rs4132601
IKZF1
Gender
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
rs6954833 rs10235796 rs4132601 rs4509706 rs4948487 rs10821936 rs4948496 rs4948502
IKZF1 ARID5B Gender
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lity Strong relevance
Edge
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Associated
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Confounded
Figure 1 Illustration of different dependency relations between certain SNPs in ARID5B and IKZF1 genes, gender and ALL
susceptibility. Top panel: The “averaged structure” of the Bayesian networks including ALL susceptibility (red node), gender (purple node) and
the SNPs of ARID5B (blue nodes) and IKZF1 (orange nodes). The width of the edges is proportional to their a posteriori probability. The probability
of the edges is computed by averaging over the Bayesian networks visited by the MCMC process. See Methods. Bottom panel: The posterior
probability of strong relevance (blue columns), edge (direct strong relevance, red columns), pure interaction (green columns), association (purple
columns), transitive association (yellow columns) and confounded association (brown columns) of the variables to ALL susceptibility according to
the BN-BMLA method.
Lautner-Csorba et al. BMC Medical Genomics 2012, 5:42 Page 7 of 15
http://www.biomedcentral.com/1755-8794/5/42of each SNP influenced the susceptibility to ALL, and
found that in all cases the homozygous states are asso-
ciated with higher risk (OR between 1.9 - 2.1) than the
carrier status, or heterozygous states.
We calculated the linkage disequilibrium (LD) coeffi-
cients between the different SNPs (Additional file 3), and
found that in both genes, the significantly associated
SNPs were in strong linkage with each other. This means
that there is only one, but strong signal in each gene. We
also evaluated the effect of different haplotypes on the
risk to ALL. We found two haplotypes (Additional file 4),
which influenced the susceptibility to ALL in the IKZF1
gene. But the odds ratio associated with the haplotypes,Table 4 Summary of the significant results of logistic regressi
Gene SNP ALL B-ALL
P-value OR 95% C.I. P-value OR
IKZF1 rs6964969 1.67E-05 1.50 1.25-1.80 1.17E-07 1.70
IKZF1 rs11978267 2.46E-05 1.50 1.24-1.79 2.97E-07 1.68
IKZF1 rs4132601 1.69E-05 1.50 1.25-1.80 2.22E-07 1.69
ARID5B rs10821936 7.31E-05 1.43 1.20-1.71 1.95E-05 1.53
ARID5B rs7089424 1.17E-04 1.42 1.19-1.69 2.68E-05 1.52
ARID5B rs4506592 1.72E-04 1.40 1.18-1.67 3.35E-05 1.51
STAT3 rs3816769 3.76E-02 0.83 0.69-0.98 4.23E-02 0.82
STAT3 rs12949918 5.15E-02 0.84 0.71-1.00 6.37E-02 0.84
*Hyperdiploid ALL; Tag SNPs are bold, as well as P-values, which reached the p < 3were not higher than in the case of individual SNPs.
Interestingly, however, a haplotype containing the major
alleles of the two individually associated SNPs (rs4132601,
rs6964969) in the IKZF1 gene shows a slight protection
against ALL (OR=0.73 (0.62-0.86); P = 3.0E-04).
Subsequently, it was investigated whether these SNPs
influence the clinical characteristics of ALL. As can be
seen in Table 4 all the SNPs which were associated with
ALL, increased the risk of B-cell ALL, but not of T-cell
ALL. When the hyperdiploid ALL (≥ 50 chromosomes)
was considered, two SNPs in the STAT3 gene
(rs3816769, rs12949918) showed decreased risk to this
clinical subtype of the disease. As these SNPs are in LDon analyses
T-ALL HD-ALL*
95% C.I. P-value OR 95% C.I. P-value OR 95% C.I.
1.40-2.08 1.88E-01 0.76 0.50-1.14 8.72E-02 1.36 0.96-1.94
1.38-2.05 2.11E-01 0.77 0.51-1.16 5.08E-02 1.42 1.00-2.02
1.38-2.06 3.46E-01 0.83 0.55-1.23 9.13E-02 1.36 0.95-1.94
1.26-1.85 3.90E-01 1.17 0.82-1.66 5.72E-03 1.61 1.15-2.27
1.25-1.84 4.14E-01 1.16 0.81-1.65 6.70E-03 1.60 1.14-2.24
1.24-1.83 6.70E-01 1.08 0.76-1.54 1.24E-02 1.55 1.10-2.19
0.67-0.99 5.82E-01 0.91 0.64-1.29 1.34E-04 0.62 0.49-0.79
0.69-1.01 5.54E-01 0.90 0.64-1.27 2.32E-04 0.64 0.50-0.81
.42E-04; FDR(α)= 1% significance threshold.
Figure 3 Overall survival rates according to the risk groups
(LR= low risk; MR=medium risk; HR=high risk).
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one signal. Interestingly, these SNPs do not influence
the risk to ALL in general.
We also investigated whether the gender of the
patients influence the effect of the SNPs, but found no
such effect.
Survival of ALL patients
We also investigated which factors influence the 5- year-
survival of the patients. We have data about the survival
rate in 516 cases (95% of all patients). Our sample set
contains similar rate of relapsed patients to what was
observed in the whole population [8]. However, the rate
of died patients is lower in our study population
(p < 0.001). Patients who died during the chemotherapy
due to therapy resistant progressive disease or due to
infections or toxicities of therapy are underrepresented
in our sample.
The overall survival rate was 85.5% (n = 441) in our
childhood ALL population (Figure 2).
There was no significant difference between sex
groups and study protocols in overall survivals. There
was significant difference between risk groups in overall
survivals (p = 1E-7). The survival rates were 92.6% in the
low, 87.0% in the medium and 62.3% in the high risk
groups (Figure 3).
The event-free survival rate was 81.0%. There was no
significant difference between sex groups and study pro-
tocols in event-free survivals. There was significant dif-
ference between risk groups in event-free survivals
(p = 1E-7). The survival rates were 90.4% in the low,
82.6% in the medium and 60.4% in the high risk groups.Figure 2 Overall survival rate of the ALL patients by
survival time.SNPs influencing the survival of the ALL patients
We investigated, whether the SNPs in our study influ-
enced the survival of the patients. Altogether 4 SNPs in
3 genes (rs10403561 and rs874966 in CEBPA, rs3024979
in STAT6, rs11667351 in BAX) were nominally signifi-
cant in this respect, but none of them reached our sig-
nificance threshold. Among these results the rs11667351
in the BAX gene showed the strongest association and
gave the lowest p value (P = 0.001; Additional file 5). The
detailed results of these SNPs can be seen in Additional
file 6. The overall and the event-free survival did not dif-
fer in this respect.
BN-BMLA method for ALL susceptibility
Besides evaluating our results with the traditional
frequentist-based methods, we also analyzed them with
our newly developed BN-BMLA method. Because the
results and their interpretation differ from those of the
standard statistical methods, here, in the results section
we also give some explanations for their understandings.
As the results of the BN-BMLA are strongly influ-
enced if the studied SNPs are in LD with each other,
we selected 48 tag SNPs. Gender was also involved in
the analysis as a variable. For each variable (SNPs and
gender) we calculated posterior probability for strong
relevance. Posterior values are between 0 and 1, where 0
indicates no relevance, 1 indicates 100% relevance be-
tween a predictor and a target variable. According to
our previous considerations [12,13], a variable is relevant
when its posterior of strong relevance is greater than or
equal to 0.5. Above 0.75 the relevancy is regarded as
convincing, between 0.5 and 0.75 as moderate.
Table 5 Posterior probabilities of strong relevance of
some variables in different groups
Phenotype ALL B-ALL T-ALL HD-ALL Risk group
Gender 0.01 0.06 0.85* 0.07 0.08
rs10821936 (ARID5B) 0.76* 0.95* 0.02 0.14 0.05
rs12949918 (STAT3) 0.01 0.00 0.01 0.60* 0.00
rs17405722 (STAT3) 0.23 0.24 0.21 0.37 0.09
rs12457893 (BCL2) 0.02 0.01 0.24 0.57* 0.05
rs1893806 (BCL2) 0.02 0.00 0.02 0.01 0.42
rs3212713 (JAK3) 0.03 0.11 0.17 0.56* 0.01
rs3087253(CCR5) 0.03 0.10 0.15 0.56* 0.00
rs2282883 (AhR) 0.01 0.00 0.11 0.08 0.42
rs2066853 (AhR) 0.06 0.04 0.25 0.34 0.04
rs4132601 (IKZF1) 0.97* 1.00* 0.02 0.02 0.00
*relevant posteriors (Posterior probability > 0.5); HD-Hyperdiploid.
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Additional file 7. The most relevant SNPs and genes (i.e.
with high posteriors for strong relevance) according to
the BN-BMLA are presented in Table 5. In case of ALL
susceptibility, the most relevant SNPs are rs10821936 in
ARID5B and rs4132601 in IKZF1. The probability that
these SNPs are directly associated to ALL is 0.76 for
rs10821936 and 0.97 for rs4132601, respectively. Both of
these direct associations are even more probable in case
of the B-cell lineage sample group (0.95 and 1.0 for
rs10821936 and rs4132601, respectively). However, in
case of the T-cell lineage sample group, the probability
of the direct relevance of these SNPs is very low, namely,
around 0.02. As the B-cell lineage is lot more frequent,
the high probability of the strong relevance of these
two SNPs in case of ALL susceptibility is probably due
to their strong relevance in B-cell lineage.
In the T-cell lineage, only the gender of the patient has
a high probability of direct association to ALL suscepti-
bility (0.85), where males have significantly higher odds
of developing ALL than women (OR= 2.28, C.I. 95%:
1.32 – 3.93).
In the hyperdiploid sample group, the probabilities of
the most relevant SNPs are moderate. Namely,
rs12949918 in STAT3 has 0.6, rs12457893 in BCL2 has
0.57, rs3212713 in JAK1 has 0.56, and rs3087253 in
CCR5 has 0.56 probability of being strongly relevant to
the hyperdiploid phenotype.
Detailed characterization of association relations
In the context of genetic association studies, strongly
relevant variables with respect to a phenotype represent
the genetic and phenotypic factors that directly influence
the phenotype (e.g. disease susceptibility). However, the
standard concept of pairwise association is not identical
to the concept of strong relevance.The association of a genetic variant to a phenotypic
feature can have multiple types (Figure 1). First, the
causal SNP has a direct influence on the phenotype. In
this case the probability of the existence of a direct edge
between the causal SNP and the phenotypic variable will
be high. Second, due to linkage disequilibrium or evolu-
tionary patterns, the genetic factors are often dependent
on each other. Because of this dependency, univariate
association tests can not necessarily make the distinction
between the true causal SNP and the SNPs that are
strongly linked to it. In these cases, the association is
mediated by the causal SNP, and there exists a path be-
tween the associated SNP and the phenotypic variable
with high probability. The association is transitive if the
path is directed, and confounded if it is not. Third, if a
SNP has no main effect on the phenotype, but has an
epistatic effect along with another factor, then this SNP
is not associated (according to the standard concept of
association), but strongly relevant to the phenotype (i.e.
it is in pure interaction with the phenotype).
We computed the a posteriori probability of the differ-
ent association types with respect to ALL susceptibility
in all sample groups (Additional file 7). Here, we present
some examples how the results in Additional file 7 can
be interpreted. The probability of the association of the
SNPs in ARID5B (rs4509706, rs4948487, rs10821936,
rs4948496, rs4948502) to ALL susceptibility are equal or
greater than 0.8, but only rs10821936 can be stated as
directly relevant, because its posterior of strong rele-
vance is 0.76 and the posterior of strong relevance is
below 0.13 in case of all other SNPs, which indicates
their non-causal, non-functional role. The situation is
same in case of the SNPs in the IKZF1 gene. The associ-
ation of the SNPs rs6954833, rs10235796, and rs4132601
in IKZF1 to ALL susceptibility is highly probable (0.97),
but only rs4132601 has a high probability (0.97) of being
strongly relevant. These effects are more expressed in
the B-cell lineage sample group.
The probability of pure interaction is very low (below
0.1) in case of all SNPs in ALL susceptibility and B-cell
lineage sample groups. However, in other sample groups,
there are some SNPs with low probability of being in
pure interaction to the phenotype, e.g. 0.43 in case of
rs3212713 in JAK3 in the hyperdiploid sample group,
and 0.42 in case of rs2282883 in AHR when the target
variable was the risk group of the patients.
Redundancies and interactions
The Bayesian analysis offers a principled way to compute
the measure of interaction or redundancy of two (or
more) SNPs. In this context, interaction means that two
SNPs tend to occur together more often in the hypo-
theses of the strongly relevant variable sets than it is
expected (i.e. the joint strong relevance of the two SNPs
Figure 4 Redundancies and interactions according to the BN-BMLA method. The figure shows the magnitude of redundancies (blue
curved lines) and interactions (red curved lines) between the variables in the whole dataset (i.e. ALL susceptibility, A panel), in the T-cell lineage
sample group (B panel) and in the hyperdiploid sample group (C panel) according to the BN-BMLA method. See Methods for the computation
of interaction and redundancy. The width of the curved lines is proportional to the strength of the effect. The a posteriori probability of the
strong relevance of the variables is proportional to the length of the dark red columns next to the variable in the inner gray colored ring.
The corresponding genes and chromosomes of the SNPs are shown on the outer ring.
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univariate relevance). On the other hand, redundancy
means that two SNPs are somewhat interchangeable in
the hypotheses of the strongly relevant variable sets (i.e.
the probability of the joint strong relevance of two SNPs
is lower than it is expected). We computed the redun-
dancies and interactions between all variables in case of
all sample groups. In Figure 4, we present the results in
a graphical form in case of the whole dataset (ALL sus-
ceptibility), the T-cell lineage patient group and the
hyperdiploid patient group. The analysis did not result
in any interactions or redundancies in case of the other
sample groups.
In case of ALL susceptibility, rs10821936 in ARID5B
and rs17405722 in STAT3 showed a weak interaction
(Interaction ratio (IR) = 0.15) and two SNPs in ARID5B,
namely rs10821936 and rs4509706 showed a moderate
redundancy (Redundancy ratio (RR) = 0.33). ARID5B and
IKZF1 (the two genes that have the highest posterior of
strong relevance to ALL susceptibility) showed no inter-
action or redundancy with each other.
In case of T-cell lineage sample group, the gender
showed a weak interaction with three SNPs in three
genes, namely rs703817 in STAT6 (IR = 0.16), rs4987845
in BCL2 (IR = 0.1), and rs1143684 in NQO2 (IR = 0.11).
This latter could be confirmed by logistic regression
analysis, as well. This indicated, that male status
increased the risk of T cell ALL, but carrying an allele of
rs1143684 slightly decreased the risk (interaction tag:
p = 0.039, OR= 0.565, C.I. 95%: 0.33 – 0.97).
In case of the hyperdiploid sample group, several over-
lapping components (i.e. sets of SNPs) were found that
showed strong interaction. The component with the
highest interaction ratio (IR = 3.06) consists of four SNPsin four genes, namely rs17405722 in STAT3, rs12457893
in BCL2, rs10208033 in STAT1, and rs3124603 in
NOTCH1. The component with the second highest
interaction ratio (IR = 2.72) consists of three SNPs in
three genes, namely rs17405722 in STAT3, rs11888 in
JAK3, and rs2030171 in STAT1. The third component
(IR = 0.86) consists of three SNPs, rs3212713 in JAK3,
rs3087253 in CCR5, and rs10235796 in IKZF1. Since
these datasets are relatively small, exact characterization
of these effects needs further validation.Survival analysis with BN BMLA
All calculated posterior probabilities in event-free sur-
vival (EFS) and overall survival (OS) are presented in
Additional file 8, and the most relevant variables in
Table 6. In both cases, lineage (B- or T-cell) and risk
group were found to be strongly relevant to the target
variable (event-free and overall survival indicator) with
high probability. However, it is more probable that
lineage is in pure interaction (P = 0.68 in EFS) than it
has a direct relevance (P = 0.09 in EFS). Its effect is
mediated by the risk group, thus lineage is important
only if risk group is known (Figure 5).
In both cases, the strongly relevant genetic factors
with the highest probability are rs11667351 in BAX (0.79
in EFS, and 0.87 in OS), and rs10403561 in CEBPA (0.63
in EFS, and 0.62 in OS). Besides, a SNP in STAT6,
namely rs703817 can be indicated as strongly relevant in
case of OS (P = 0.67), but its probability is lower in case
of EFS (P = 0.34).
We computed the redundancies and interactions
between all variables in both survival types, as well. The
results are shown in Figure 6.
Table 6 Posterior probabilities of the most relevant variables in event-free and overall survival
Event-free survival Overall survival
Strong relevance Edge Pure interaction Strong relevance Edge Pure interaction
Lineage (T- or B-cell) 0.77 0.09 0.68 0.79 0.12 0.67
Risk group 0.99 0.99 0.00 1.00 1.00 0.00
rs4509706 (ARID5B) 0.11 0.03 0.08 0.54 0.26 0.28
rs703817 (STAT6) 0.34 0.32 0.02 0.67 0.65 0.02
rs10403561 (CEBPA) 0.63 0.63 0.00 0.62 0.62 0.00
rs11667351 (BAX) 0.79 0.78 0.01 0.87 0.87 0.01
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In this study we presented our results of a candidate
gene association study in childhood acute lymphoblastic
leukemia evaluated by traditional frequentist-based
methods and our newly developed BN-BMLA method.
According to the frequentist-based evaluation, among
the successfully genotyped 62 SNPs in 19 genes, 6 SNPs
in 2 genes associated with increased susceptibility to
ALL. But, as the SNPs in both genes were in LD,
this corresponded to one signal in each gene, namely
in ARID5B and IKZF1. Both associations were specific
for B-cell ALL, and in all loci the effect on risk was
dose-dependent, as homozygous states associated with
higher risks.
ARID5B belongs to a family of transcription factors
important in embryonic development, cell type–specific
gene expression, and cell growth regulation. SNPs in the
gene have been found associated with ALL in several
previous genome wide and candidate gene association
studies and in different populations [3,4,6,20]. In some
studies the associations were restricted to B-
hyperdiploid ALL and to males. In our study no such
difference was found between boys and girls, and the
SNPs were not associated with hyperdiploidy, but theLineage
rs11667351
BAX
Event-free
survival
Risk group
rs10403561
CEPBA
Figure 5 Subgraphs of the strongly relevant variables in event-free a
of the strongly relevant variables in event-free survival according to the BN
the strongly relevant variables in overall survival according to the BN-BMLA
probability. Edges are shown only if their a posteriori probability exceed 0.5
Bayesian networks visited by the MCMC process. See Methods. Target varia
color, and SNPs with orange color.important role of the gene in B-cell ALL susceptibility
was confirmed. It must be added, however, that all of the
associated SNPs in the ARID5B gene are in intron, and
presently it is not known, how they influence the risk to
ALL.
SNPs in the IKZF1 gene were identified by indep-
endent genome wide association studies in Caucasian
children; although later in some studies and in some
populations the association was not confirmed [3,4,21].
IKZF1 (encoding the lymphoid transcription factor
IKAROS) is deleted in approximately 80% of the Phila-
delphia chromosome–positive ALL with constitutively
active BCR-ABL1 tyrosine kinase [22,23]. Furthermore,
Ikaros proteins are master regulators of lymphocyte de-
velopment, thus IKZF1 is a good candidate gene for
ALL. Earlier, one of the SNPs, the rs4132601, which
showed an association with increased susceptibility to
ALL, and influenced in an in vitro system the expression
level of the gene in a dose-dependent fashion, with lower
expression being associated with the risk alleles [4].
Since human and mouse studies suggest that diminished
expression of IKZF1 interrupts lymphocyte develop-
ment, creating conditions that maintain the rapidly div-
iding lymphoblasts that characterize ALL, the lowerLineage
rs11667351
BAX
Overall
survival
Risk group
rs10403561
CEPBA
rs703817
STAT6
nd overall survival. Left: The “averaged structure” of the subgraphs
-BMLA method. Right: The “averaged structure” of the subgraphs of
method. The width of the edges is proportional to their a posteriori
. The probability of the edges is computed by averaging over the
bles are indicated with red color, phenotypic variables with purple
Figure 6 Interactions in event-free and overall survival according to the BN-BMLA method. The figure shows the magnitude of
interactions (red curved lines) between the variables in the event-free survival (A panel), and in the overall survival (B panel) according to the
BN-BMLA method. See Methods for the computation of interaction. The width of the curved lines is proportional to the strength of the effect.
The a posteriori probability of the strong relevance of the variables is proportional to the length of the dark red columns next to the variable
in the inner gray colored ring. The corresponding genes and chromosomes of the SNPs are shown on the outer ring.
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ute to the increased risk to the disease.
SNPs in the STAT3 gene were found to decrease the
risk to hyperdiploid ALL. The signal transducer and acti-
vator of transcription protein 3, encoded by STAT3, has
been identified as a regulator of cell survival after expos-
ure to apoptotic signals [24-26]. STAT3 serves, among
others, as a substrate for SYK tyrosine kinase. SYK is
capable of associating with and phosphorylating STAT3
in human B-lineage leukemia/lymphoma cells challenged
with oxidative stress [27]. Inhibition of SYK with a small
molecule drug candidate prevented oxidative stress-
induced activation of STAT3 and overcame the resist-
ance of human B-lineage leukemia/lymphoma cells to
apoptosis. The decreased risk associated with the SNPs
in the STAT3 gene in our study correlates with the
results of other studies, e.g. the rs12949918 SNP was
found to be associated with decreased susceptibility to
different malignancies, like risk to B-cell non-Hodgkin
lymphoma or renal cell carcinoma [28]. According to
in vitro studies, the SNP affects STAT3 mRNA levels,
with the minor allele having a lower STAT3 expression
[29]. Presently it is not known how it might influence
the risk to hyperdiploid ALL.
We also investigated whether the SNPs influence the
survival of the disease. It must be noted, however, that
the rate of died patients is lower in our study population
(p < 0.001), than in the whole Hungarian ALL population
(see Methods), thus our results could be biased in this
respect. In the frequentist-based evaluation, the
rs11667351 in the BAX gene showed the strongest asso-
ciation and gave the lowest p value (P = 1E-3), but it still
did not reach the significance threshold (P ≤ 3.42E-4).Next, we evaluated our results with the BN-BMLA
method. Earlier, we applied this method to evaluating a
partial genome screening in asthma [13]. In that study
the frequentist-based method identified two genes for
asthma susceptibility (FRMD6 and PTGDR), while the
BN-BMLA identified 3 additional genes. When we ana-
lyzed the cause of this difference, it turned out that the
other 3 genes indirectly associated with asthma risk, i.e.
in different gene-gene interactions. Then, as BN-BMLA
is also capable of analyzing multiple targets, we involved
additional phenotypic, target variables in the analysis. In
this case the BN-BMLA identified 3 additional genes.
The SNPs in these genes influenced the susceptibility to
asthma through other target variables, like rhinitis, IgE,
or eosinophil levels. As all of these phenotypic variables
are in strong association with asthma, association with
these might also cause association with the disease. This
latter is called transitive associations.
In the present study we could not involve additional
target variables in the evaluation, as there are no com-
mon known phenotypic characteristics in controls,
which significantly change the risk to ALL. The BN-
BMLA could confirm the association of SNPs in the
ARID5B and IKZF1 to B-cell ALL with high posterior
probability. Additionally, however, as explained in the
detailed characterization of association relation, the
results of the analysis gave additional information about
the nature of the relations between the SNPs and the
disease. In this case no strongly relevant interactions
were found, but the analysis suggested several weak
interactions. E.g. in case of ALL susceptibility,
rs10821936 in ARID5B and rs17405722 in STAT3
showed a weak interaction, and in case of T-cell lineage
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with three SNPs in three genes (Figure 4). Interestingly
e.g., as it is also known from the scientific literature, the
male gender increased the risk of T-cell ALL, but carry-
ing an allele of rs1143684 in the NQO2 gene slightly
decreased the risk. The BN-BMLA is also capable of cal-
culating redundancy of the variables. E.g. in the present
study the rs10821936 and rs4509706 SNPs in ARID5B
gene, showed a moderate redundancy, i.e. their effects
are interchangeable with each other. It is also an import-
ant finding, that there are no interactions or redundan-
cies between the two most relevant genes, ARID5B and
IKZF1. This is also a confirmation of the results of other
studies where no interactions were found between the
two genes [30].
Several interactions have been detected in hyperdi-
ploid ALL (Figure 4 C). Although the number of patients
in this group is relative low, thus the results must be
handled with some reservations, most of these interac-
tions are biologically plausible. E.g. in our analysis a
strong interaction was found among SNPs in the
NOTCH1, STAT1, STAT3 and BCL2 genes. In the scien-
tific literature it is known that STAT3 is activated in the
presence of active Notch. Notch-IC stable transfectants
increased STAT1-dependent transcription in response to
IFN-gamma. In a zebra fish model of human NOTCH1-
induced T-cell leukemia, the leukemia onset was dra-
matically accelerated when the transgenic fish was
crossed with another line over expressing the zebra
fish Bcl2 gene, indicating synergy between the Notch
pathway and the Bcl2-mediated antiapoptotic pathway
[31-33]. All of these results suggest that the pathways
represented by these genes are overlapping and there are
interactions between them.
Analyzing the effects of the variables on the survival of
the patients with BN-BMLA resulted in two SNPs in
two genes with strong relevance. The relevance of
the rs11667351 SNP in the BAX gene was convincing
(posterior probability > 0.75), while that of the rs1040356
in the CEBPA gene was moderate. As can be seen in
Figure 6, the SNP in the BAX gene was also involved in
an interaction with a SNP in the BCL2 gene. This inter-
action is biologically plausible, as there are a lot of
known interactions between the products of the two
genes [34]. E.g. BCL2 prevents BAX/BAK oligomeri-
zation, and BCL2 binds to and inactivates BAX. There
are also data, although inconclusive, about the role of
BAX in the relapse of children with ALL. High levels of
BAX protein have been associated with an increased
probability of relapse in one study, while in another
study both BAX expression levels and the BAX/BCL2
ratio were significantly lower in samples at relapse com-
pared to samples at initial diagnosis [35,36]. In ourstudy, children homozygous to the minor allele of the
rs11667351 SNP had a very poor survival rate (40%,
Additional file 5 and Additional file 6). In a study, this
variant was associated with lower BAX mRNA in lym-
phocytes. It must be added, however, that the number
of patients homozygous to the minor allele of the
rs11667351 was very low in our population.
The protein encoded by CEBPA is a transcription fac-
tor which can bind as a homodimer to certain promoters
and enhancers. Its mutations have been found to be
implicated in acute myelogenous leukemia with favor-
able prognosis [37]. In our study minor allele carrier sta-
tus showed better survival rate, than major allele
homozygotes, suggesting certain concordance between
the two observations.
The BN-BMLA also detected known connections be-
tween risk groups, lineage and survival, but also revealed
some possible interactions between certain variables like
gene-gene, lineage-gene or lineage-gender (Figure 6).
Evaluating the effect of SNPs on the survival rate
of the patients resulted in some discrepancies between
the two methods. The frequentist-based method
detected only nominally significant associations, which,
according to the accepted rules, have to be rejected,
while the BN-BMLA, especially in the case of the BAX
gene found strong, convincing relevancy. It is generally
accepted, that the frequentist-based methods cannot
properly handle the multiple testing problem. To avoid
type I error, sometimes the frequentist methods are too
conservative and unable to detect weak effects or inter-
actions. The findings of the BN-BMLA are biologically
plausible, but additional studies are needed to confirm
these results.
In the present paper we show the ability of BN-BMLA
to evaluate a candidate gene association study. As can be
seen from the results, the advantage is not that the BN-
BMLA can detect more relevant variables, but the
Bayesian networks offer a rich language for the detailed
representation of types of relevance, including direct and
indirect aspects. Additionally, Bayesian statistics offer an
automated and normative solution for the multiple hy-
pothesis testing problems [11]. In this study we could
not utilize the full potential of the BN-BMLA, since we
could not include multiple targets present also in con-
trols, we did not have data from different sources (e.g.
from gene expression analysis) and did not involve
data from other databases and did not involve a priori
knowledge in our evaluation. Furthermore, the investi-
gated population was relative small. Childhood acute
lymphoblastic leukemia is a relative rare disease, with
an incidence of 50–70 cases in a year in Hungary. In
this respect the 543 ALL children in this study can
be regarded as a large population. However, in a gene
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very difficult to detect in such a population weak effects
or gene-gene interactions. Still, the BN-BMLA was able
to reveal, besides the strongly relevant ARID5B and
IKZF1 polymorphisms, several possible interactions, and
showed the possible types of them. According to our
studies in larger, artificial datasets, if there are real com-
plex interactions among the variables, the method is able
to reveal complex network of interactions, significantly
more complex than in Figure 1 in this study [12].
The Bayesian statistical framework allows the calcula-
tions of posteriors over a wide range of hypotheses,
such as strong relevance of variables, pairs of variables,
triplets of variables, etc. [9-13]. This shows the advan-
tage of the Bayesian framework, because it allows the
selection of appropriate level of complexity of hypoth-
eses, which is not possible in the traditional hypothesis
testing approach. Furthermore, this Bayesian global rele-
vance analysis method provides posteriors, which are
direct statements about hypotheses, thus it can also be
used to construct probabilistic data analytic knowledge
bases in genetic association studies to support complex
quering, off-line meta-analysis, and fusion with back-
ground knowledge.
We offer the BN-BMLA method for academic pur-
poses. The tool is available at a public website [38].Conclusion
In the present study we confirmed the role of genetic
variations in ARID5B and IKZF1 in the susceptibility to
B-cell ALL. In our population we found that genetic var-
iations in the STAT3 gene might influence the suscepti-
bility to hyperdiploid ALL. We presented the survival
rate of a relatively large number of Hungarian children
with ALL, and investigated the effects of some genetic
and other variables on the survival rate. We also evalu-
ated our results with our newly developed BN-BMLA
method, which confirmed the relevance of SNPs in the
ARID5B and IKZF1 genes in B-cell ALL with high pos-
terior probabilities. Furthermore, the results of the ana-
lysis gave additional information about the nature of the
relations between several SNPs and the disease. In the
different subgroups of patients, the BN-BMLA revealed
several types of relations. Evaluating the survival rates
of the patients, the BN-BMLA showed that besides risk
groups and subtypes, genetic variations in the BAX
and CEBPA genes might also influence the survival of
the patients.
In the present paper we showed several advantageous
features of the BN-BMLA method, and we demonstrated
that in gene association studies it might be a useful
supplementary to the traditional frequentist-based statis-
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